Metrics as of 10/17/2026, 05:03 AM (Berlin time), refresh in progress.
Lonza Group Stock
Lonza Group AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- Wolfgang Wienand
- Employees
- 20,141
- Market cap
- CHF42.2 B
- IPO
- 01/11/1999
Lonza Group AG, headquartered in Basel, Switzerland, operates as a contract development and manufacturing organization within the healthcare sector and biotechnology industry. The company provides services to pharmaceutical and biotech companies across Europe, North and Central America, Latin America, Asia, Australia,…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Lonza Group stock: price history
1D
+0.0%
1W
+5.6%
1M
+12.2%
6M
+11.2%
YTD
+12.3%
1Y
+10.2%
2Y
+12.7%
5Y
-16.3%
10Y
+258.3%
Next earnings date
Next earnings date
27/01/2027 (in 102 days)
Volatility around earnings
~23% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Lonza Group stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 01/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Lonza Group AG operates as a contract development and manufacturing organization serving the global pharmaceutical and biotechnology industries. The business model is segmented into integrated biologics, advanced synthesis, and specialized modalities including mRNA, cell and gene therapies, and microbial platforms. Its scope spans from clinical development through active pharmaceutical ingredient manufacturing to finished drug product production. Through the deployment of highly specialized technologies, the company addresses complex requirements in small molecules, antibody-drug conjugates, and bioconjugates.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Lonza Group
Analyst assessment of Lonza Group
0
STRONG BUY
1
BUY
2
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Hold
As of: 22/02/2021
Lonza Group stock metrics
P/E
-392.21
P/B
5.2
EV/EBITDA
21.3
RETURN ON EQUITY
7.3%
NET MARGIN
17.5%
DEBT/EQUITY
0.51
DIVIDEND YIELD
0.8%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.9%
FLOAT SHARES
69,741,488
AVG. DAILY VOLUME (30D)
134,230
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Lonza Group stock
What does Lonza Group do?
Lonza Group AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is Wolfgang Wienand, the company employs around 20,141 people.
The IPO was on 01/11/1999; the stock trades on SIX under the ticker LONN.SW.
What do analysts say about Lonza Group stock?
3 analysts rate the stock, the consensus is Hold (as of 22/02/2021).
This is an external assessment, not a statement by Market Jury.
When does Lonza Group report next?
The next earnings date is 27/01/2027.
Around past earnings, price swings were roughly 23% stronger than usual.
Does Lonza Group pay a dividend?
Yes. The last dividend was CHF 5.00 per share, ex-date 12/05/2026, paid on 15/05/2026.
The dividend yield is 0.8% (as of 30/06/2026).
Which stocks are comparable to Lonza Group?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Basilea Pharmaceutica, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and argenx.
How can I get Lonza Group stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lonza Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.